September Sales and Targets. Next Month Plan

1. Month Performance
uMx Khan.
Lahore, Pakistan.
Novartis-OTC Devision.

2. Overview
 Sales
Performance
 Sample Management
 KPI Performance
 Activities Execution
 BMD Review
 MAT
 Next Month Objectives & Planning

3. Sales Performance
Brands
CAC 1000 PLUS COLA 10
CAC 1000 PLUS COLA 20
CAC 1000 PLUS I.C 10
CAC 1000 PLUS ORANGE T10
CAC 1000 PLUS ORANGE T20
CAC 1000 PLUS PINEAPPLE 10
OPTALIDON TABS
QALSAN-D ORANGE 30
QALSAN-D TABS STRW 30
QALSAN-D TABS MIX 30
QALSAN-D TABS MNT 30
SANCOS
SPASMO CIBALGIN
T-DAY TABS
T-DAY SYRUP
VOLTRAL EMULGEL20G
VOLTRAL EMULGEL50G
LAMISIL CREAM
BENEFIBER 150 G
BENEFIBER SACHET S-10
BENEFIBER SACHET S-30
Total Value
CaC 1000 Plus
Qalsan-D
T Day
VEG
Lamisil
Benefiber
Target
Sep
Ach.
417
227
87
10,127
654
64
315
3,047
3,334
1,544
60
406
763
1,363
68
127
133
368
45
527
225
26
7,053
913
177
421
2,648
2,246
2,184
1,229
47
842
966
1,459
101
110
188
228
35
1,927,637
1,051,358
545,658
79,583
125,514
21,559
52,476
%age
YTD
Ach.
Target
126
99
30
70
140
275
133
87
67
141
#DIV/0!
#DIV/0!
79
208
127
107
149
87
142
62
%age
1,385
846
350
32,535
2,535
408
1,887
8,450
9,084
3,918
1,729
11,643
382
1,600
2,545
5,689
281
502
437
1,055
1,454
550
126
29,619
2,804
266
1,899
8,001
11,401
4,160
1,988
14,648
330
1,932
3,496
4,626
301
480
626
919
105
65
36
91
111
65
101
95
126
106
115
126
86
121
137
81
107
96
143
87
79
205
123
60
1,838,525
845,353
571,971
146,872
139,775
18,761
95
80
105
185
111
87
6,970,324
3,493,533
1,596,074
300,153
523,705
85,402
6,974,106
3,216,207
1,759,152
375,012
439,608
81,724
100
92
110
125
84
96
53,644
102
173,591
188,336
108

4. Target
1%
6%
5%
2% 2%
23%
61%
CaC Plus
Qalsan D
VEG
T.Day
Lamisil
Benefiber
Others

5. Achievement in %age
185
87 102
112
105
80%
Cac Plus
Qalsan D
VEG
T.Day
Lamisil
Benefiber
Others

6. Overall
1928
1579
1600
1400
1763
1200
1000
743
800
Target
Achievement
%
600
400
120%
200
4%
0
Total
SPLY

7. CaC Plus
1200
1000
1051
1086
824
770
686
800
600
Target
Achievement
%
475
400
120%
200
112%
316
109 290%
0
CaC
Plus
T10
T20
129%
SPLY

8. Qalsan D
571
300
250
545
214
200
Target
Achievement
%
129
150
100
50
105%
67%
0
Qalsan D
SPLY

9. VEG
140
139
132
120
100
92
125
76
80
Target
Achievement
%
60
40
40
111%
20
0
VEG
20g
107%
8
50g
48
149%
SPLY
111%

10. T.Day
90
145
81
80
70
80
58
60
50
45
Target
Achievement
%
43
40
30
2023
20
10
185%
208%
127%
0
T.Day
Tab
Syp
86%
SPLY

11. Lamisil
16
15
15
14
12
10
10
8
Target
Achievement
%
6
6
4
87%
137%
2
0
Lamisil
SPLY

12. Sample Management
Allocated
Executed
175
174
Qalsan D
100
80
T.Day
176
176
VEG
130
130
Cac Plus
Lamisil

13. KPI Performance
T V
U 1
2
3
A
45 45 0 0
2
10 28 5 100 115 16 149 171 20
B
70 67 3 0
62 8
0
0 96
85
136 116
C
45 24
0
0
0 53
53
45
21
24
0
4
5 C
F
A TV AV W
24

14. Activities Execution
Allocated
Operated
Rx
Cac Plus
4
4
35
VEG
2
2
22
T.Day
2
2
25
Lamisil
1
1
7
Total
9
9
93

15. Next Month Objectives & Planning
Achieve Monthly Budget and deficit.
 CaC Plus Budget.
 Osonate, Fastum Gel, Rigix Tab.
 Pace of Lamisil Cream.
 Meeting KPI.
 Resources Utilization.
 Activities Execution.


16. Thank You.